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OBJECTIVE — To evaluate whether use of oral hypoglycemic agents is associated with an
altered breast cancer risk in women.
RESEARCH DESIGN AND METHODS — Using the U.K.-based General Practice Re-
searchDatabase,weconductedanestedcase-controlanalysisamong22,621femaleusersoforal
antidiabetes drugs with type 2 diabetes. We evaluated whether they had an altered risk of breast
cancer in relation to use of various types of oral hypoglycemic agents. Case and control patients
with a recorded diagnosis of type 2 diabetes were matched on age, calendar time, and general
practice, and the multivariate conditional logistic regression analyses were further adjusted for
useoforalantidiabetesdrugs,insulin,estrogens,smokingBMI,diabetesduration,andHbA1c(A1C).
RESULTS — We identiﬁed 305 case patients with a recorded incident diagnosis of breast
cancer.ThemeanSDagewas67.510.5yearsatthetimeofthecancerdiagnosis.Long-term
use of 40 prescriptions (5 years) of metformin, based on 17 exposed case patients and 120
exposedcontrolpatients,wasassociatedwithanadjustedoddsratioof0.44(95%CI0.24–0.82)
fordevelopingbreastcancercomparedwithnouseofmetformin.Neithershort-termmetformin
use nor use of sulfonylureas or other antidiabetes drugs was associated with a materially altered
risk for breast cancer.
CONCLUSIONS — A decreased risk of breast cancer was observed in female patients with
type 2 diabetes using metformin on a long-term basis.
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T
ype2diabeteshasbeenrelatedtoan
elevatedriskofvariouscancertypes.
Manystudieshaveindicatedthatdi-
abetes is associated with a modestly in-
creased risk of postmenopausal breast
cancer (1), although some authors found
no such association, as discussed in detail
by Xue and Michels (1).
Type 2 diabetes is characterized by
insulin resistance and hyperinsulinemia.
Aside from its metabolic effects, insulin
also has mitogenic effects that are medi-
ated through the IGF-I receptor and insu-
lin receptor (2). Epidemiological studies
have demonstrated that insulin resistance
andhyperinsulinemiaarerelatedtoanin-
creased risk of epithelial malignancy, in-
cluding breast, prostate, colon, and
kidney (2,3). It was shown that higher
levelsoffastinginsulininwomenwithout
diabetes were associated with an in-
creasedriskofbreastcancerdevelopment
(4).Furthermore,diabeteswasassociated
with markedly increased mortality in
women with breast cancer (5). Therefore,
improving insulin resistance and correct-
ing hyperinsulinemia may be an effective
strategy to reduce both the risk of devel-
oping breast cancer and the risk of breast
cancer-related mortality.
Metformin is known to improve hy-
perinsulinemia and insulin resistance
mainly by decreasing hepatic gluconeo-
genesisandincreasingglucosedisposalin
muscle. Use of metformin was associated
with a decreased risk of cancer in patients
with type 2 diabetes in various observa-
tional studies; however, the authors did
not provide detailed information on the
risk of breast cancer (6,7). In another ep-
idemiological study, users of metformin
hadsigniﬁcantlydecreasedcancer-related
mortality compared with users of either
sulfonylureas or insulin (8). Recently,
Currie et al. (9) observed no alteration of
breastcancerriskinassociationwithmet-
formin use in a subgroup analysis in their
retrospective cohort study. Female dia-
betic patients receiving neoadjuvant
chemotherapy for breast cancer were re-
ported to have a higher complete patho-
logic response rate if they also used
metformin compared with those not us-
ing metformin (10). Recently, Landman
et al. (11) reported a lower cancer-related
mortality for metformin users compared
with that for nonusers. Anisimov et al.
(12) showed that metformin increased
the life span and decreased development
of spontaneous mammary tumors in
HER-2/neu transgenic mice. Further
work in breast cancer cells demonstrated
that metformin does not act as an “insu-
lin-sensitizing” drug, but as a growth in-
hibitor; growth inhibition was mediated
byupregulationofAMP-activatedprotein
kinase (AMPK) activity and downstream
suppression of signaling through the
mammalian target of rapamycin (13,14).
These studies suggest that metformin ex-
erts direct antitumor activity mainly by
activation of AMPK and consequently in-
terferes with cancer cell metabolism.
To date, there is only sparse evidence
from epidemiological studies addressing
the association between metformin and
the risk of breast cancer. Because breast
cancer is a frequently diagnosed cancer
and because the studies mentioned above
suggest a probable effect of metformin on
breast cancer development and growth,
we conducted a case-control analysis to
explore the association between long-
termuseofmetforminandotherhypogly-
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breast cancer.
RESEARCH DESIGN AND
METHODS— Datawerederivedfrom
the U.K.-based General Practice Research
Database (GPRD) (15). In brief, this data-
base was established around 1987 and
currently encompasses some 5 million
people who are enrolled with selected
general practitioners, covering 50
million person-years of follow-up. The
patients enrolled in the GPRD are repre-
sentative of the U.K. with regard to age,
sex, geographic distribution, and annual
turnover rate. General practitioners have
been trained to record medical informa-
tionincludingdemographicdata,medical
diagnoses, hospitalizations, deaths, and
drug prescriptions using standard soft-
ware and standard coding systems. The
general practitioners generate prescrip-
tions directly with the computer, and this
information is automatically transcribed
into the computer record. It contains the
name of the preparation, instructions for
use, route of administration, dose, and
number of tablets for each prescription.
The recorded information on drug expo-
sure and diagnoses has been validated
andproventobeofhighquality(16).The
GPRDhasbeenthesourceofmanyobser-
vationalstudies,includingresearchondi-
abetes and antidiabetes drugs (17–19)
and on cancer (20). The study was ap-
proved by the Independent Scientiﬁc Ad-
visory Committee for Medicines and
Healthcare products Regulatory Agency
database research.
We ﬁrst identiﬁed all subjects in the
GPRD who had a diabetes diagnosis
and/or who received at least one pre-
scription for an oral hypoglycemic drug
includingsulfonylureas,biguanides,thia-
zolidinediones, -glucosidase inhibitors,
or prandial glucose regulators, with or
without concomitant insulin use, and
who were between the ages of 30 and 79
years between 1994 and 2005. Diabetic
patients who received only insulin were
not included. We excluded all patients
with 3 years of recorded history in the
database before the date of the ﬁrst diabe-
tes diagnosis or the ﬁrst prescription for
an antidiabetes drug (whichever came
ﬁrst), as well as all patients with alcohol-
ism and women with a diagnosis of gesta-
tional diabetes at any time in their record.
Withinthisdiabeticstudypopulation
aged 30–79 years, we then identiﬁed all
women followed up to 89 years of age
whohad,aftertheﬁrstprescriptionforan
oral antidiabetes drug, a recorded ﬁrst-
time diagnosis of either invasive breast
cancer or carcinoma in situ which was
followed by breast surgery, radiation,
chemotherapy, antiestrogen therapy (ta-
moxifenoranastrazole),oracombination
thereof. The date of this ﬁrst diagnosis of
interest will be referred to as the “index
date.”
Withinthestudypopulationweiden-
tiﬁed at random up to four control pa-
tients per breast cancer case patient,
matched to case patients on age (same
year of birth), sex, general practice, and
indexdate(i.e.,thecontrolpatientgotthe
same index date assigned, i.e., the date of
theﬁrst-timerecordedcancerdiagnosisof
the case patient). The aim of matching for
index date was to compare drug exposure
between case and control patients at the
same point in time to avoid confounding
by calendar time.
As with the case patients, control pa-
tients also had to have their ﬁrst exposure
to an oral antidiabetes drug recorded be-
fore the index date, and they also had to
be free of any cancer diagnosis before the
index date.
Statistical analysis
Weconductedanestedcase-controlanal-
ysis, whereby we assessed exposure to
oral antidiabetes drugs and insulin from
the computer records before the index
date in case and control patients. We
classiﬁed users of antidiabetes drugs
according to the drug class (insulin, sul-
fonylureas, metformin, thiazolidinedio-
nes, prandial glucose regulators, or
-glucosidase inhibitors) and the dura-
tion of use, based on the number of pre-
scriptionsreceived(none,1–9,10–39,or
40 prescriptions). Based on the average
number of tablets per prescription, the
category of 40 prescriptions reﬂects an
exposure duration of 5 years. We
conducted conditional logistic regression
analyses using SAS 9.1 (SAS Institute,
Cary, NC) to compare the exposure prev-
alence between cancer case patients and
control patients. Risk estimates are pre-
sentedasoddsratios(ORs)with95%CIs.
P values are two-sided and considered
statistically signiﬁcant if P  0.05. We
comparedmetforminuserswithnonusers
ofmetformin(includingusersoftheother
oral hypoglycemic drugs) and adjusted
themultivariatemodelforuseofsulfonyl-
ureas, thiazolidinediones, insulin, and
other oral antidiabetes drugs to evaluate
whether an alteration of the OR for breast
cancer among metformin users may be
confounded by use of other oral antidia-
betes drugs. We also evaluated duration
of use of oral antidiabetes drugs, compar-
ing each level of duration with nonusers
of the respective drug class. We further
adjusted the model for smoking status
(none, current, past, and unknown), BMI
(25, 25–29.9, and 30 kg/m
2), dura-
tion of diabetes (1 year, 1–2 years, and
2years),andthelastreportedA1Clevel
(6.5%, 6.5–7.4%, 7.5–8.9%, and
9%) before the index date as well as for
use of postmenopausal estrogens (none,
1–19, and 20 prescriptions). We also
assessed whether case and control pa-
tients had renal failure, congestive heart
failure, ischemic heart disease, stroke/
transient ischemia attack, hypotension,
hypertension, or dyslipidemia and ex-
plored whether these diseases con-
founded the association between use of
oral antidiabetes drugs and the risk of
breast cancer, both in univariate models
and in the ﬁnal multivariate model. For
this purpose, we included potential con-
founders one by one in the model to see
whether they altered the main association
of interest, i.e., use of antidiabetes drugs
and the risk of developing breast cancer.
Because none of these parameters materi-
ally altered the OR of developing breast
cancer, we did not include them in the
ﬁnal model. We further assessed use of
aspirin,tamoxifen,orraloxifeneaswellas
the number of breast biopsies recorded
before the index date. Because these pa-
rameters also did not alter the OR in the
multivariate analysis, we did not include
them in the ﬁnal model.
RESULTS— Thestudypopulationen-
compassed 22,621 women who received
at least one prescription for at least one
studydrug.Withinthisstudypopulation,
we identiﬁed 305 case patients with a re-
cordedincidentdiagnosisofbreastcancer
who fulﬁlled our inclusion criteria, with a
meanSDageof67.510.5yearsatthe
timeofthecancerdiagnosis.Thematched
control sample encompassed 1,153 can-
cer-freewomen.Thus,wehad3.8control
patients per case patient on average and
266 of 305 (87%) sets had a full 4:1
match. Characteristics of case and control
patients are displayed in Table 1, and Ta-
ble 2 presents detailed data about the var-
iousantidiabetesdrugcombinationsused
by case and control patients.
Overall, the OR for any versus no
metformin use was 1.03 (95% CI 0.76–
1.39), adjusted for use of insulin, sulfo-
nylureas, thiazolidinediones, prandial
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BMI, use of postmenopausal estrogens,
diabetes duration, and A1C level. When
we stratiﬁed metformin use by exposure
duration, use of short duration was not
associated with a materially altered OR,
whereas long-term use of metformin, de-
ﬁned as 30 prescriptions, was associ-
ated with an adjusted OR of 0.63 (0.39–
1.00) for developing breast cancer, based
on 33 case patients and their control pa-
tients compared with nonuse. If we de-
ﬁned long-term use of metformin as 40
prescriptions, the adjusted OR was 0.44
(0.24–0.82, P  0.01), based on 17 case
patients and their control patients com-
pared with nonuse of metformin (Table
3). Further adjustment for congestive
heart failure, ischemic heart disease, or
renal failure did not modify the OR of in-
terest (data not shown). The OR for long-
term use (20 prescriptions before the
index date) of estrogens in the multivari-
atemodelwas2.22(1.38–3.55),adjusted
foruseofmetformin,useofotherantidia-
betes drugs BMI, smoking, diabetes dura-
tion, and A1C. Neither short- nor long-
term use of sulfonylureas was associated
with an altered OR of breast cancer (ad-
justed OR 1.03, 95% CI 0.62–1.70 for
users of 40 prescriptions) in this multi-
variate model (Table 3).
In an additional analysis, we assessed
theeffectoforalantidiabetesdrugsonthe
OR of developing breast cancer after ex-
cludingallinsulinusers.TheadjustedOR
for users of 40 metformin prescriptions
compared with nonusers of metformin
was 0.42 (95% CI 0.21–0.87, P  0.02),
whereas it remained virtually unaltered
for users of other oral antidiabetes drugs
(Table 4).
CONCLUSIONS — In this observa-
tional study in a population of women
with type 2 diabetes, we found a de-
creased risk of breast cancer in women
who used metformin for several years,
whereasnosucheffectwasseenforshort-
term use. The association was similar
when we removed insulin users from the
analysis. In a previous observational
study of 983 cancers, Evans et al. (6) re-
ported an overall decreased risk of cancer
for metformin users (31 prescriptions,
adjusted OR 0.73, 95% CI 0.56–0.94).
However, the authors did not provide
data stratiﬁed by individual cancer types,
nordidtheyreportwhetheruseofinsulin
was excluded or controlled for in their
analyses (6). Libby et al. (7) reported an
adjusted hazard ratio (HR) for cancer of
0.63(95%CI0.53–0.75)inpatientswith
type 2 diabetes in metformin users versus
nonusers of this drug. Again, no speciﬁc
information on the breast cancer risk was
available. In a similar study, Currie et al.
(9) observed that metformin mono-
therapy carried the lowest risk of cancer
among patients with type 2 diabetes;
however, they found no risk alteration in
breast cancer patients using metformin.
In another population-based study using
administrative data from Saskatchewan,
Bowker et al. (8) found an increased can-
cer-related mortality for patients with
type 2 diabetes who used sulfonylureas
(adjusted HR 1.3, 95% CI 1.1–1.6) or in-
sulin compared with metformin users.
Several clinical studies in pre- and
postmenopausalwomenwith(1)orwith-
out (21) type 2 diabetes revealed a signif-
icantly higher risk of breast cancer in
association with hyperinsulinemia and
insulin resistance. Furthermore, high
fasting insulin levels and obesity have
been associated with poor cancer-related
outcome(4).Boththereductionofhyper-
insulinemia and growth inhibition via
AMPK activation might explain why met-
formin therapy seems to be associated
with a decreased risk of breast cancer.
This has been hypothesized by various
authors (22,23) and is supported by the
current ﬁndings.
Thiazolidinediones, like metformin,
are known to correct hyperinsulinemia
and insulin resistance, and their use may
also be associated with diminished breast
cancer development or growth. In our
Table 1—Characteristics of female breast cancer case patients and their control patients
Case patients Control patients Crude OR (95% CI)*
n 305 1,153
Age (years)
40 5 (1.6) 7 (0.6) —
40–49 14 (4.6) 57 (4.9) —
50–59 40 (13.1) 167 (14.5) —
60–69 99 (32.5) 359 (31.2) —
70–79 113 (37.0) 445 (38.6) —
80 34 (11.2) 118 (10.2) —
BMI (kg/m
2)
25 48 (15.7) 174 (15.1) 1.00 (referent)
25–30 100 (32.8) 356 (30.9) 1.01 (0.68–1.48)
30 138 (45.3) 526 (45.6) 0.95 (0.65–1.38)
Unknown 19 (6.2) 97 (8.4) 0.69 (0.38–1.27)
Smoking status
Nonsmoker 190 (62.3) 677 (58.7) 1.00 (referent)
Current 32 (10.5) 168 (14.6) 0.71 (0.47–1.07)
Past 71 (23.3) 245 (21.2) 1.08 (0.78–1.48)
Unknown 12 (3.9) 63 (5.5) 0.66 (0.33–1.31)
Estrogen use
Nonuser 220 (72.1) 902 (78.2) 1.00 (referent)
1–19 prescriptions 49 (16.1) 174 (15.1) 1.18 (0.82–1.70)
20 prescriptions 36 (11.8) 77 (6.7) 2.10 (1.34–3.28)
Diabetes history (years)
1 57 (18.7) 216 (18.7) 1.00 (referent)
1–2 55 (18.0) 194 (16.8) 1.14 (0.74–1.76)
2 193 (63.3) 743 (64.5) 1.07 (0.74–1.54)
A1C (%)
6.5 69 (22.6) 239 (20.7) 1.00 (referent)
6.5–7.4 72 (23.6) 275 (23.9) 0.91 (0.62–1.33)
7.5–8.9 62 (20.4) 233 (20.2) 0.92 (0.62–1.39)
9 51 (16.7) 187 (16.2) 0.89 (0.58–1.38)
Unknown 51 (16.7) 219 (19.0) 0.68 (0.42–1.10)
Renal failure 10 (3.0) 43 (3.7) 0.78 (0.38–1.63)
Congestive heart failure 15 (4.9) 88 (7.6) 0.65 (0.37–1.14)
Ischemic heart disease 60 (19.7) 218 (18.9) 1.09 (0.78–1.52)
Data are n (%) unless otherwise indicated. *Adjusted for age, sex, general practice, and calendar time by
matching.
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thiazolidinediones was too small to allow
robust analyses. There was, however, a
tendency toward an increased relative
breast cancer risks for long-term users
(10 prescriptions) of thiazolidinedio-
nes, but the ﬁnding did not reach statisti-
cal signiﬁcance. A possible association
between use of thiazolidinediones and an
altered risk of cancer has recently been
described (24). The authors reported a
33% reduction in lung cancer risk among
users of thiazolidinediones compared
with nonusers (for whites, adjusted HR
0.74,95%CI0.58–0.95).However,they
did not report whether they also assessed
metformin use and breast cancer risk.
There are several limitations in our
study that need to be acknowledged.
First, there may be some misclassiﬁcation
of cancer diagnoses because we did not
sendformedicalrecordsforbreastcancer
case patients to get a ﬁnal conﬁrmation of
the cancer, e.g., via histology. However,
the GPRD has been used numerous times
for studying cancer, and previous valida-
tion studies provided convincing evi-
dence that most cancer diagnoses are
recorded with high validity in the GPRD
(90%)(20).Furthermore,weassesseda
random sample of case report forms and
veriﬁed the validity of our inclusion crite-
ria as explained in RESEARCH DESIGN AND
METHODS. In addition, any misclassiﬁca-
tion would probably have occurred at
randomandwouldnotbeassociatedwith
use of a particular oral antidiabetes drug
such as metformin. Second, although we
analyzed a large number of patients with
breastcancer,wewerenotinapositionto
differentiate them according to standards
in clinical oncology because of a lack of
information about staging, histology, and
molecularbiologyofthesetumors.Third,
we lacked some clinical information on
glycemiccontrol(e.g.,detailedreportson
bloodglucoselevels)aswellasriskfactors
such as physical activity or nutritional
habits. However, we assessed both dura-
tion of diabetes and level of A1C and im-
portant complications of diabetes (e.g.,
ischemic heart disease, stroke, and renal
failure), but all of these variables did not
alter the OR for breast cancer either in the
univariate or in the multivariate model.
Fourth, because of the lack of reliably re-
corded data, we could not assess age at
menarche, age at ﬁrst birth, parity, and
family history of breast cancer. Although
all of these are known to be associated
with an altered breast cancer risk, it is
highly unlikely that these parameters are
associated with the type of oral antidiabe-
tes drug used by a women later in life and
therefore confounded the main associa-
tion of interest. Furthermore, we could
not assess the risk of breast cancer in as-
sociation with use of antihyperglycemic
agents across different ethnicities, be-
cause this information is not routinely
available. Fifth, our conclusions are
mainlybasedonthesubgroupof17long-
termmetforminusersand120controlpa-
tients, relying, although statistically
signiﬁcant, on a relatively small number
of case and control patients. However, we
did not observe a similar effect among
long-term users of other oral antidiabetes
drugs, and we think that our ﬁnding may
be biologically reasonable because cancer
development may not be signiﬁcantly im-
paired by short-term drug use.
In conclusion, our observational
study provides evidence that long-term
use of metformin may be related to de-
creased breast cancer risk. However, lim-
ited by the observational study design, a
conclusion of association by causality
cannot be drawn. Our ﬁndings add to the
increasingbodyofevidenceandmayhelp
Table 2—Antidiabetic drug utilization among breast cancer cases and control patients
Antidiabetic drug use Case patients Control patients
n 305 1,153
None 68 (22.3) 255 (22.1)
Insulin only 0 (0) 2 (0.1)
Sulfonylureas only 64 (21.0) 250 (21.7)
Metformin only 62 (20.3) 198 (17.3)
Insulin and sulfonylureas 7 (2.3) 25 (2.2)
Insulin and metformin 4 (1.3) 22 (1.9)
Sulfonylureas and metformin 55 (18.1) 263 (22.8)
Insulin, sulfonylureas, and metformin 23 (7.5) 64 (5.5)
Other* 22 (7.2) 74 (6.4)
Data are n (%). *Any combination of the above drugs with a thiazolidinedione, acarbose, or a prandial
glucose regulator.
Table 3—Breast cancer risk in users of oral antidiabetic drugs and users of insulin
Drug and no.
prescriptions
Case
patients
Control
patients
Unadjusted OR
(95% CI)*
Adjusted OR
(95% CI)† P value‡
n 305 1,153
Metformin
None 140 540 1.00 (referent) 1.00 (referent)
1–9 64 205 1.21 (0.86–1.72) 1.20 (0.82–1.78) 0.35
10–39 84 288 1.16 (0.85–1.60) 1.09 (0.76–1.55) 0.65
40 17 120 0.55 (0.31–0.97) 0.44 (0.24–0.82) 0.01
Sulfonylureas
None 138 492 1.00 (referent) 1.00 (referent)
1–9 62 243 0.87 (0.61–1.23) 0.85 (0.58–1.24) 0.39
10–39 71 292 0.87 (0.62–1.20) 0.79 (0.55–1.15) 0.22
40 34 126 0.96 (0.62–1.49) 1.03 (0.62–1.69) 0.92
Thiazolidinediones
none 285 1,084 1.00 (referent) 1.00 (referent)
1–4 4 24
5–9 4 15
10 12 30 1.59 (0.80–3.17) 1.76 (0.84–3.68) 0.13
Insulin
none 262 1,022 1.00 (referent) 1.00 (referent)
1–9 18 49 1.51 (0.86–2.66) 1.74 (0.95–3.21) 0.07
10–29 11 40 1.13 (0.57–2.26) 1.30 (0.62–2.70) 0.49
30 14 42 1.35 (0.72–2.54) 1.51 (0.76–3.01) 0.24
Data are n unless otherwise indicated. *Adjusted for age, sex, general practice, and calendar time by
matching. †Adjusted for age, sex, general practice, and calendar time by matching and further adjusted for
eachotherplususeofprandialglucoseregulators,acarbose,estrogens,smoking,BMI,diabetesduration,and
A1C ‡P values relate to the adjusted model.
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uating metformin in patients with hyper-
insulinemia (e.g., type 2 diabetes) and
breast cancer, as discussed (22,23),
planned by other authors (25), or already
done retrospectively (10).
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Table 4—Breast cancer risk in users of oral antidiabetic drugs excluding insulin users
Drug and
prescriptions
Case
patients
Control
patients
Adjusted OR
(95% CI)* P value
n 262 1,022
Metformin
None 132 509 1.00 (referent) —
1–9 55 172 1.40 (0.94–2.09) 0.10
10–39 64 253 0.97 (0.67–1.42) 0.89
40 11 88 0.42 (0.21–0.87) 0.02
Sulfonylureas
None 132 468 1.00 (referent) —
1–9 49 208 0.90 (0.61–1.32) 0.58
10–39 54 241 0.84 (0.57–1.24) 0.38
40 27 105 1.11 (0.65–1.88) 0.70
Dataarenunlessotherwiseindicated.*Adjustedforage,sex,generalpractice,andcalendartimebymatching
and further adjusted for each other plus use of prandial glucose regulators, acarbose, thiazolidinediones,
estrogens, smoking, BMI, diabetes duration, and A1C.
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